Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
Saved in:
| Title: | Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity. |
|---|---|
| Authors: | Brum MCM; Program of Molecular and Cellular Oncobiology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil., Dos Santos Guimaraes I; Division of Clinical Research, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil., Ferreira LB; Program of Molecular and Cellular Oncobiology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil., Rangel LBA; Departament of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, Espírito Santo 29040‑090, Brazil., Maia RC; Stricto Sensu Graduate Program in Oncology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil., Nestal De Moraes G; Stricto Sensu Graduate Program in Oncology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil., Gimba ERP; Program of Molecular and Cellular Oncobiology, National Institute of Cancer, Rio de Janeiro 20231‑050, Brazil. |
| Source: | Oncology reports [Oncol Rep] 2021 Feb; Vol. 45 (2), pp. 652-664. Date of Electronic Publication: 2020 Dec 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2431 (Electronic) Linking ISSN: 1021335X NLM ISO Abbreviation: Oncol Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
